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a b s t r a c t 
Background: Stigma is an important element in the experience of living with chronic viral hepatitis B (HBV) and 
C (HCV), impacting healthcare access and uptake as well as health outcomes. Conceptualisations of stigma in 
research are, however, often assumed and implicit. This study aimed to synthesise and critically engage with the 
qualitative literature to provide an overarching conceptualisation of stigma as it pertains to viral hepatitis. 
Methods: We critically reviewed qualitative literature that mobilised concepts or theories of stigma in relation to 
viral hepatitis. We searched seven electronic databases for peer-reviewed literature from 2000 to 2019. Given a 
dearth of conceptual literature on HBV stigma, we conducted a thematic analysis of concepts deployed to theorise 
stigma in relation to HCV. 
Results: We found 13 studies that conceptualised stigma in relation to HCV, yet none for HBV. We synthesise 
the analytical findings of these studies and explore how HCV is theorised in relation to four themes: ‘identity’, 
‘embodiment’, ‘institutionalisation’, and ‘structuration’. Taken together, these themes illustrate the way in which 
HCV stigma manifests as the confluence of normative assumptions of socially unacceptable practices relating 
to HCV, such as injecting drug use and sexual behaviours; attitudes towards socially excluded populations; and 
fears of contracting a contagious and chronic illness. As such, operating within political, social, and economic 
systems, HCV stigma can act to silence the needs of those with HCV through misrecognising the multifaceted 
identities of individuals with HCV and structural determinants of health. Stigma, which is built and perpetuated 
by institutional arrangements, as well as in social processes and policies, shapes deservedness to, as well as 
engagements with, health and social care. 
Conclusion: While commonly employed as a framing concept, much research lacks explicit theoretical or critical 
engagement on how stigma is conceptualised. There is a tendency for qualitative, empirical research to focus 
on risk factors shaping individual behaviour change, rather than on risk contexts and socio-structural change. 
Approaches to address stigma in relation to HCV must consider how stigma operates throughout social processes 

















Chronic viral hepatitis B (HBV) and hepatitis C (HCV) infection is
 major public health threat and affects an estimated 325 million peo-
le globally. If left untreated, viral hepatitis can lead to hepatocellular
arcinoma and cirrhosis, and contributes to some 1.4 million deaths an-∗ Corresponding author. 
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ty (290 million) of people with viral hepatitis are unaware of their
tatus and are therefore not engaged with the formal healthcare sys-
em for viral hepatitis care and treatment. The World Hepatitis Alliance
as emphasised social stigma as a critically important factor shaping
ccess to viral hepatitis testing, diagnosis, and care ( World Hepatitis
lliance, 2018 ). Addressing stigma is a key step towards reaching na-
ional and global targets to eliminate viral hepatitis as a major pub-
ic health threat ( A National Strategy for the Elimination of Hepati-
is B & C, 2017 ; Commonwealth of Australia, 2018 ; World Health Or-
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Inclusion and exclusion criteria. 
Inclusion Exclusion 
Original academic research Editorials, commentaries, reports, 
or reviews 
Use of qualitative methodology 
such as focus groups, interviews, 
and observations (can be part of a 
larger mixed-methods study) 
No use of qualitative methodology 
(e.g., surveys and questionnaires) 
Published from 2000 to 2019 Published before 2000 
Explicit engagement, analysis, or 
theorisation of stigma associated 
with viral hepatitis 
Description of stigma associated 
with viral hepatitis without 
further engagement, analysis, or 
theorisation 
Published, peer-reviewed research Research not yet published or 
peer-reviewed 
Reported in English or Spanish Reported in any language other 









































nd its adverse effects as a common feature of the lived experience
f viral hepatitis, primarily arising from misconceptions of infection
nd transmission ( Dowsett, Coward, Lorenzetti, Mackean, & Clement,
017 ; Lee, Fawcett, Kim, & Yang, 2016 ; Liu, 2016 ; Mokaya et al., 2018 ;
aterson, Backmund, Hirsch, & Yim, 2007 ; Treloar, Rance, & Backmund,
013 ). Additionally, many individuals with viral hepatitis belong to
arginalised populations, such as people who are experiencing hom-
essness or who use drugs, or engage in practices which are subject
o various forms of stigma, such as injecting drugs ( World Health Or-
anization, 2017 ). Stigma is also reproduced in healthcare practices
nd settings ( Mokaya et al., 2018 ; Paterson et al., 2007 ), resulting
n fragile trust in experts and services ( Treloar, Rance, & Backmund,
013 ), especially amongst those most vulnerable with least access to
are ( Harris, Ward, & Gore, 2016 ; Rhodes, Harris, & Martin, 2013 ).
onsequently, experiences of stigma can preclude access to care and
eter help-seeking, even in the face of need ( Lee et al., 2016 ; Liu, 2016 ;
hodes et al., 2013 ). As such, understanding how stigma entangles with
iral hepatitis, and how such stigma affects health-seeking behaviours,
ccess to care, and the care received, is fundamental to addressing viral
epatitis ( World Health Organization, 2017 ). 
A paradigm shift in HCV treatment ( Cooke et al., 2019 ), accompa-
ied by a global commitment to eliminate viral hepatitis as a major
ublic health threat by 2030 ( World Health Organization, 2016 ), re-
uires reconsideration of stigma as a mobilising concept that informs
ealthcare and other interventions. A growing body of literature mea-
ures stigma in relation to viral hepatitis using quantitative indicators,
etrics, or scales, based on recalled and reported lived experiences
 Cotler et al., 2012 ; Drazic & Caltabiano, 2013 ; Paterson et al., 2007 ;
aine et al., 2020 ; Soltan, Salama, & Aboelmagd, 2018 ). The translation
f stigma into indicators enables mapping and monitoring in relation to
he frequency, intensity, and location of stigma occurrences, which can
hen be linked to analyses of risk or health outcomes ( Butt, Paterson,
 McGuinness, 2008 ). Much of this work, however, does not explic-
tly define or unpack what is meant by ‘stigma’ per se, but assumes a
hared understanding. Qualitative studies provide valuable insight into
he ways in which stigma is experienced and how these impact health
utcomes and decision-making processes ( Butt et al., 2008 ). However,
ven within qualitative research, conceptualisations of stigma tend to
e assumed and implicit rather than carefully delineated and critically
eflected upon. In this review, we synthesise concepts generated from a
maller body of qualitative research in which there is an explicit theori-
ation or critical engagement with stigma as it pertains to viral hepatitis.
At the time of writing, there has been no targeted synthesis of the
onceptual literature on viral hepatitis-related stigma. An early review
 Paterson et al., 2007 ) sought to critically examine published research
epresentations of HCV stigmatisation, with a focus on how these un-
erstandings have informed healthcare interventions. Similar to other
esearch ( Van Boekel, Brouwers, Van Weeghel, & Garretsen, 2013 ), the
hematic presentation of findings of Paterson et al. (2007) are orien-
ated towards elucidating the determinants of HCV stigma in healthcare
ettings, rather than to conceptual development or critique. Likewise,
reloar, Rance, & Backmund (2013) in a later review maps HCV stigma
n relation to healthcare uptake and access, highlighting the modifying
ole of trust in facilitating relationships of care, but stops short of crit-
cally reflecting upon how the social construct of stigma itself is to be
perationalised or theorised going forwards. More recent reviews act
o map determinants of stigma ( Saine et al., 2020 ) or synthesise litera-
ure on living with HCV with attention to the pervasive and detrimental
mpact of stigma on people’s lives ( Dowsett et al., 2017 ). 
A lack of critical attention to the concept of stigma itself is due in
art to the influence of Goffman’s definition of stigma as an “attribute
hich is deeply discrediting ”, whereby those who are stigmatised be-
ome “reduced in our minds from a whole and usual person to a tainted,
iscounted one ” (1963, p. 3). Notwithstanding this seminal contribution
f stigma as a social construct, an implicit or uncritical application of
offman’s conceptualisation risks focusing on stigma as an “individual2 ragedy ”, best ameliorated through individualised coping methods and
nterpersonal level interventions ( Link & Phelan, 2001 ; Parker & Aggle-
on, 2003 ). In making this critique, Link and Phelan (2001) alert to the
ole of power and structural inequity in the manifestation of stigma,
hrough processes such as labelling, stereotyping, and discrimination
 Link & Phelan, 2001 ). Recent contributions to the field, and specifi-
ally in relation to drug use and viral hepatitis, highlight stigma and
ts effects variably, for instance, as a matter of socio-political relations
 Fraser et al., 2017 ; Seear, 2020 ; Tyler & Slater, 2018 ), or discursive
ractices ( Toyoki & Brown, 2014 ). As such, ‘stigma’ is not a singular or
table category, but rather it is open to theorisation and deployment in
esearch in variable ways; as further illustrated in this review. 
ethodology 
In this review, we map the ways in which stigma, as it pertains to
iral hepatitis, has been variously conceptualised in a select body of
ualitative literature. Through thematic analysis and synthesis of the
oncepts deployed, we aim to advance theory building with a practi-
al remit of informing future stigma reduction interventions for people
iving with viral hepatitis. 
ligibility criteria 
Included studies were original, peer-reviewed, qualitative research,
ncluding ethnographies or case studies, that include perspectives of
eople living with viral hepatitis or their care providers (see Table 1 ).
e included studies published from 2000 to reflect advances in stigma
heorisation over the past two decades and to coincide with the launch
f the Millennium Development Goals, reflecting a renewed global focus
n infectious diseases. Studies must have generated analyses in relation
o viral hepatitis stigma and also to have provided an explicit conceptu-
lisation of stigma in this context. 
As the aim of this paper was to synthesise conceptualisations of
tigma related to viral hepatitis within the qualitative evidence base,
e excluded studies that reference stigma as a taken-for-granted con-
ept without providing any definitional work around the term. While
e recognise that qualitative studies may produce empirical descrip-
ions which can then be theorised, we only included studies that pro-
ided an explicit theorisation of stigma related to viral hepatitis. We
lso excluded editorials, commentaries, and reviews. The reference lists
f reviews were, however, searched to find additional studies and frame
he synthesis rather than to be incorporated as material for the main
nalysis. 
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Table 2 
Search strategy example. 
Web of Science #1 ‘viral hepatitis’ OR ‘Hepatitis C’ OR ‘Hepatitis B’ OR 
‘HCV’ OR ‘hep c’ OR ‘hepatitis c’ OR ‘hepatitis c virus’ 
OR ‘hep c virus’ OR ‘HBV’ OR ‘hep b’ OR ‘hepatitis b’ 
OR ‘hepatitis b virus’ OR ‘hep b virus’ 
#2 ‘social stigma’ OR ‘social discrimination’ OR stigma ∗ 
OR prejudice OR attitude OR marginalization OR 
shame 
#3 ‘qualitative research’ OR qualitative OR interview OR 
‘focus group’ OR experience OR perception OR 
ethnography OR perspective 







































































H  nformation sources 
In December 2019, we searched the following electronic databases:
ubMed, Medline, CINAHL, Anthropology Plus, SocIndex, PsycINFO,
nd Web of Science from 2000 to 2019. Search terms included terms
elated to viral hepatitis, stigma, and qualitative research, and MeSH
ere used where applicable (see Table 2 ). We also conducted forward
itation searching of relevant articles using tools in PubMed and Google
cholar. 
tudy selection 
After running the initial search, articles were imported into Mende-
ey Desktop version 1.19.4. After removing duplicates, articles were
roadly screened from search output on the basis of titles and abstracts
y DG. DG conducted forward searching and hand-searched the ref-
rences of these eligible articles for those not indexed in the selected
atabases. These articles were then screened on the basis of titles and
bstracts by MH and TR, disagreements were resolved with DG and JVL.
fter screening based on titles and abstract, articles were screened on
he basis of full-text for inclusion by DG, CAP, TMW, and MH. Disagree-
ents were resolved with JVL. 
ata collection process and data items 
Two independent reviewers (DG and CAP) extracted data into a pre-
pecified data extraction template. Information included authors, title,
tudy aims, design, setting, population, stated theoretical or analytical
ramework, methods of data generation and analysis, and a brief sum-
ary of how stigma was conceptualised by the authors. Data were ex-
racted by one reviewer (DG) and validated by another (CAP). Differ-
nces were reconciled amongst three reviewers (DG, CAP, TMW). Table 3 
Analytical codes. 
1. Stigma is conceptualised as intrinsic (self-stigma a
2. Stigma is conceptualised as extrinsic (enacted stigm
3. Stigma is organised hierarchically in relation to HIV
4. Stigma is organised hierarchically in relation to soc
5. Stigma is mediated by social or community identit
6. Stigma is lessened/worsened depending on HCV tra
7. Stigma arises from conflation of HCV and injecting
8. Stigma comes from the belief that those with HCV
9. Stigma emerges from fear of contagion of illness 
10. Stigma is rooted in ignorance, which stems from m
11. Stigma stems from societal aversion to chronic illn
3 ynthesis of results 
Given the absence of eligible studies addressing conceptualisations of
tigma related to HBV, we focus this analysis on HCV. Since the overar-
hing aim of studies reviewed did not have to relate to advancing stigma
heorisation, we did not assess the strengths and limitations of concep-
ualisations of HCV stigma in this regard. We conducted a thematic syn-
hesis based on principles of grounded analysis and meta-ethnography
ethods ( Barnett-Page & Thomas, 2009 ; Thomas & Harden, 2008 ). The
oncept synthesis was grounded in reading of articles reviewed and a
wo-stage inductive coding process, rather than being determined by a
riori topics. Drawing on the framework of Thomas and Harden (2008) ,
hree reviewers (DG, CAP, TMW) independently analysed each study,
ssigning first level codes to describe concepts deployed in relation to
CV stigma. Summaries were made for each text to consolidate and aid
hematisation of the key conceptual findings. Following this round, five
eviewers (DG, CAP, TMW, JVL, and MH) discussed and worked with
rst level codes and summaries to consolidate and abstract them into
1 main analytical codes (see Table 3 ). Summaries were then created
or each of these codes, which the five reviewers worked with to con-
olidate into four conceptual themes relating to identity, embodiment,
nstitutionalisation, and structuration. 
Three reviewers, (DG, CAP, TMW) were randomly assigned one third
f the articles to code the text against each conceptual theme. The coding
or each article was then validated by a second reviewer from this same




The initial search yielded 3,085 records. After removing duplicates,
,998 total articles remained. After screening, 87 articles remained. Fol-
owing searching and hand-searching the references of the initial arti-
les, 12 additional articles were considered for eligibility. From these
rticles, 31 were reviewed at the full text level for final inclusion. Eigh-
een articles were excluded, primarily because they mentioned stigma
ut did not theorise or conceptualise what was meant by the term, and
pecifically in relation to HCV (see Fig. 1 ). 
tudy characteristics 
Thirteen studies were included in this review (see Table 4 ). Studies
ook place in Argentina ( n = 1), New Zealand and Australia (1), Aus-
ralia ( n = 4), Canada ( n = 2), the United Kingdom, ( n = 2) and the
nited States ( n = 3). Across all studies, there were 447 participants;
ample sizes ranged from 6 to 132. The study participants described in
he studies included healthcare workers ( n = 2), people with chronic






 drug use or people who use drugs 
 engaged in what is deemed as “risky behaviours ”
isconceptions and stereotypes of people with HCV 
ess 
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Table 4 
Characteristics of included studies. 























with HCV in 
south-eastern 
Australia 








Draws on Goffman’s 
(1963) model of 
actual and virtual 
social identity, 
focusing on stigma 
as a discrediting 
attribute, and 
Douglas (1966) 
notion of dirt and 
pollution 
Stigma in terms of HCV is built 
within the wider social context of 
the issue. The lack of alternative 
narratives of those living with 
HCV conflate HCV and injecting 
drug use, and the moral 
assumptions of this conflation 
create stigma. That is, those who 
engage in injecting drug use and 
other ‘deviant’ behaviours are 
deemed ‘tainted’, as Goffman 
describes, and therefore less 
human, which enables conscious 
or unconscious discriminatory 
practices towards them by health 
workers in health care settings. 
Although, the stigma and shame 
faced by those with HCV make 
them reluctant to disclose their 
status and perpetuate the stigma 
in the healthcare setting. 
Owen (2008) To describe the 
emotional 
experience of 
HCV stigma in 







gay men aged 
32–43 years 
living in 





















under the framework 
of Tomkins (1995) 
demonstrating that 
emotions amplify the 
significance of our 
social interactions 
Within sexual practices between 
men who have sex with men, HCV 
is more stigmatising than HIV 
since HCV is not ‘owned’ by this 
community. This demonstrates the 
hierarchical stigmatisation 
process. In particular, the fear of 
HCV can be often rooted in fears 
of obtaining HCV, complicating 
the existing troubles of managing 
HIV, sexual rejection due to HCV 
status, and lifestyle restrictions 
due to HCV, which causes the 
infection to be stigmatised within 
the community. Furthermore, this 
leads to social rejection when HCV 
is disclosed, and creates fear and 
shame, which prevents some men 
from disclosing their HCV status, 
thereby risking HCV infection 
during sexual practice. 
Lekas (2011) To explore the 
impact of the 
layered stigmas 
of HIV and 











living in New 
York City 
















felt and enacted 
stigma 
HCV-related stigma is hierarchised 
in relation to HIV, with HCV being 
more stigmatising. This stigma 
layering could mitigate and lessen 
exposure to stigma. HCV was 
perceived as a physical illness 
caused by a biological agent 
rather than a moral failing (in 
comparison to HIV), which 
decreased or eliminated stigma. It 
was also perceived as being less 
dangerous amongst many 
co-infected patients and their 
social circles, which contributed 
to lesser stigma in relation to HIV. 
Although, stigma in relation to 
HCV was rooted in the fears of 
contagion as HCV was represented 
as a highly contagious disease that 
could be passed through casual 
contact. Felt stigma in relation to 
HCV was intensified due to 
witnessing discrimination after 
disclosing their HIV status, which 
caused participants to anticipate 
stigma in relation to their HCV 
status. HCV-related stigma also 
arose through the association of 
HCV with drug use and 
contributed to the discrediting 
nature of someone with HCV. 
( continued on next page ) 
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Table 4 ( continued ) 























with HCV aged 
53 to 68 years 







( n = 5) and 
injected drug 









Unclear Stigma of HCV is rooted within 
the socio-political context of 
acquiring infection. Specifically, 
stigma is influenced by external 
attribution of blame and 
responsibility, as well as levels of 
distress and uncertainty in 
response to the diagnosis. Stigma 
here is associated with type of 
drug use (e.g., injected v. snorted), 
duration of drug use, and the 
inability to ‘overcome’ addiction. 
When people self-administered 
drugs, the blame was more 
internal and less associated with 
the diagnosis itself. When people 
obtained HCV medically (e.g., 
transfusion) they were more likely 
to externally blame individuals 
with HCV. 
Butt (2008) To identify and 
describe how 
people lived 
with HCV and 
made self-care 
decisions 
Canada Adults (aged 
18 or older) 
with chronic 
hepatitis C 
living in British 
Columbia 











Considers stigma as 





This article focuses on how stigma 
impacts a patient’s self-esteem in 
relation to their HCV status and 
how the manifestation of stigma 
occurs in events and activities 
with family members, friends, 
co-workers and in health settings. 
Authors categorise the patient’s 
response to the received stigma as 
intrinsic and extrinsic, labelling 
associated emotions to each. 
Stigma associated with HCV arises 
from cultural fears of contracting 
HCV and negative views of people 
who engage in ‘risky behaviours’, 
such as injection drug use, and 
are members of devalued social 
groups. Because of this 
association, society views people 
with HCV as dangerous and/or 
irresponsible individuals, blames 
them for having HCV, and expects 
them to disregard the safety of 
others and transmit the virus. 























Focuses on stigma as 
a part of the social 
processes of power 
and control that 
mark individuals or 
groups for social 
exclusion and draws 
on Link and Phelan’s 





HCV-related stigma within the 
Aboriginal Australian population 
was compounded by issues of 
power, status, and capital related 
to colonial legacies. Stigma is 
conceptualised as devaluing as a 
consequence of labelling and 
stereotyping rooted in their 
cultural notions of shame. Authors 
also considered stigma associated 
with the identity of being an 
Aboriginal Australian and HCV 
stigma robbed people in the 
community of the protective 
factor of community identity. 
Cama (2015) To examine 
experiences of 
and responses 
































upon them to be 
illegitimate, they 
may actively seek to 
change their 
situation 
HCV-related stigma arises from 
misinformation about the illness 
and a fear of its transmission. This 
causes discrimination against 
people with HCV, especially in 
healthcare settings. The infection 
was typically associated with 
injection drug use, which made 
some healthcare workers blame 
participants for their illness. 
Ownership and normalisation of 
HCV through the advocacy 
program allowed participants to 
claim their HCV status and make 
HCV more visible to providers and 
therefore less stigmatising. 
( continued on next page ) 
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Table 4 ( continued ) 























HCV in Nova 
















institutions, as well 
as particular hospital 
departments, as 
impacting the way in 
which healthcare 
practitioners within 
that institution or 
department respond 
to and treat people 
who use illicit drugs 
and are HCV 
positive, leading to 
the perception by 
this population that 




Stigma in relation to HCV is 
environmentally embodied. It is 
conceptualised as a multi-faceted 
concept that is fostered and 
supported by internal and external 
structures. Communication, 
institutional, and departmental 
structures within healthcare 
systems result in structural stigma 
of people who use illicit drugs 
that are HCV positive. 





United States Individuals 
with HCV and 
part of a liver 
disease 
support group 
aged from 35 
to 72 years 




















as being negatively 
judged by others as 
the result of HCV 
status 
Ignorance of HCV in terms of 
routes of transmission, standard 
precautions, workplace policies, 
and medication side effects allows 
individuals to enact stigma 
towards people living with HCV 
and results in discrimination. 
Awareness and knowledge play a 
large role in determining 
HCV-related stigma. Authors argue 
that if education of HCV is 
enhanced and addressed this may 
significantly mitigate stigma and 
its related consequences. 
Pecheny (2007) To understand 
the daily lives 









( n = 13), HCV 
( n = 5), or 
both ( n = 9) 
and health 
professionals 













on the stigmas that 
affect people and 
make them 
discreditable 
Stigma related to HCV, especially 
in terms of the health system, was 
built due to its associations with 
‘risky’ behaviours including 
injecting drug use, in addition to 
sexual identity, and lifestyle. In 
terms of the personal disclosures 
of patients, there was also a 
‘stigmatising supposition’ of 
innocent victims and those that 
deserved HCV depending on the 
mode of infection. Stigma was 
hieratically organised in relation 
to HIV, and HIV was more 
stigmatising than HCV since 
people generally were less aware 
of it. 
Harris (2009) To explore the 






















( n = 20) and 
Sydney, 
Australia 

















Draws on Crossley’s 




bodies as both 





Stigma related to HCV is rooted in 
1) the associations between HCV 
and injecting drug use, which is 
more vilified than other forms of 
drug use since it is seen as a 
bodily violation; 2) 
misconceptions of contagion due 
to a lack of public awareness 
about HCV and 3) societal views 
on chronic illness as a devalued 
bodily state and that HCV doesn’t 
fit into the typical illness 
trajectory since people with HCV 
may appear to be well externally 
but face physical symptoms and 
stigma that make them unwell 
internally. 
( continued on next page ) 
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Table 4 ( continued ) 










To explore the 
factors that 
contribute to 
the building of 
social stigma 
of HCV in rural 
communities. 




31 and 70 

















that views of 
morality are 
determined by the 
actors, culture, time, 
and setting in 
society 
HCV-related stigma is built 
through the development of the 
social hierarchy in this rural 
community, which relates to 
power, status, and social and 
economic capital. Perceptions of 
opinion leaders, who are 
financially secure and mostly 
elderly, influence the perceptions 
about community members and 
build an informal consensus about 
HCV. Being in the upper class 
makes it hard to empathise with 
people struggling with infection, 
which contributes to stigma. As 
such, stigma is related to material 
and structural disadvantages in 
society. 





with current or 
past HCV 
infection 




Builds on Goffman’s 
theory of stigma, 
which authors link 
to the binary logic 
common to thinking 
about the body, 
health, and identity 
Binary thinking (e.g., good/bad, 
clean/contaminated, well/sick) in 
Western culture is integral to 
stigma categorisations. This 
creates a clear hierarchy between 
what is deemed as ‘good’ and 
‘bad’. Therefore, the idea of being 
‘spoiled’ by having HCV is 
constructed in similar terms such 
as purity/infectious and 
health/sickness. In contrast, the 
ideal body must be clean 
(uninfected), closed (not party to 
the movement of microbes or 
other matter) and pure (blameless 



























































s  IV co-infection ( n = 2). Twelve studies analysed transcribed interview
ata, and one analysed open-ended responses from a mail-in survey. 
npacking HCV-related stigma 
We present and critically engage with analytical findings under four
hemes: identity, embodiment, institutionalisation, and structuration,
hat serve as conceptual tools in the theorisation of HCV stigma amongst
he reviewed studies. We draw on direct quotes of participants’ accounts
f HCV stigma throughout studies to highlight these themes. 
dentity 
‘I’m a father, I’m not my disease, I’m not my illness’ ( Cama, Wilson,
Mackenzie, & Brener, 2015 , p. 423). 
Cama et al. (2015) position stigma as subsuming the complexity of
n individual’s identity to one specific attribute – in this case the ‘dis-
ase’ of HCV. Similarly, the 12 other studies included in this review
ncorporated identity-based conceptualisations of HCV stigma, whereby
tigma acts in concert with social norms to disrupt a person’s sense of
elf and/or their social identity. Many of these theorisations draw on
offman’s (1963) conception of stigma as arising in interplay with soci-
tal labelling of and reactions to specific practices or attributes. While
idden, these ‘discreditable’ attributes threaten identity and when ex-
osed (‘discrediting’) they can act to ‘spoil’ a normative or socially ac-
eptable presentation of self ( Goffman, 1963 ). Here, stigma is capaci-
ated through the disavowal of a complex, multifaceted identity. 
We can think with this concept also in terms of Becker’s (1963) ‘mas-
er status’, whereby one deviant label becomes the entire identity of
he individual. Identity-focused conceptualisations of stigma in the re-
iewed literature highlight the way in which living with HCV discred-
ts in concert with social norms. For example: practices deemed ‘de-7 iant’ such as injecting drug use ( Butt et al., 2008 ; Cama et al., 2015 ;
arris, 2009a ; Henderson & Kawakami, 2018 ; Krzeczkowska, Flow-
rs, Chouliara, Hayes, & Dickson, 2019 ; Lekas, Siegel, & Lei-
er, 2011 ; Northrop, 2017 ; Paterson, Hirsch, & Andres, 2013 ;
echeny, Manzelli, & Jones, 2007 ), ‘promiscuous’ sexual relations
 Henderson & Kawakami, 2018 ; Lekas et al., 2011 ; Northrop, 2017 ;
wen, 2008 ; Pecheny et al., 2007 ) or – simply – being unable to seek
nd hold employment ( Harris, 2009a ). Negative stereotypes attached
o these practices and attributes are often rooted in societal views of
orality or productivity and act to diminish the perceived human sta-
us of individuals with HCV. 
Identity-based conceptualisations of stigma, therefore, highlight vi-
al hepatitis stigma as a form of ‘role engulfment’ ( Schur, 1971 ),
hereby the person’s identity is delimited by associations with specific
ractices (such as illicit drug use) or conditions (such as viral hepati-
is). This can be internalised as shame or fear of encountering discrim-
nation (‘felt stigma’) or enacted in practice through discriminatory be-
aviour (‘enacted stigma’) ( Fraser & Treloar, 2006 ; Scambler, 2004 ).
his conceptual focus narrows attention to the way in which experi-
nces of stigma can impact on individual decision-making, for example
n relation to the access and uptake of social and healthcare services.
orthrop (2017) , for example, highlights how felt and enacted stigma
xperienced following HCV disclosure in the healthcare setting encour-
ged some participants to change healthcare providers (and not disclose
CV status to the new provider), while others avoided the healthcare
ystem altogether. The decision not to disclose HCV status to a new
ealthcare provider is here protective, voiced in these terms: 
‘I want to be treated like every other person … and at the moment I
don’t feel I’ve been treated the same way’ ( Northrop, 2017 , p. 221).
Northrop explicitly draws on Goffman in her conceptualisation of
tigma as it relates to HCV. Her participant’s decision not to disclose
tigma is a form of identity management – a strategic manipulation of
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mpressions ( Goffman, 1959 ), regulating information to influence the
erception of others. Northrop’s work is important in illustrating how
n individual stigma management focus on regulating interpersonal in-
eractions can have ambivalent effects. In the case above, for example,
on-disclosure is deemed necessary to protect the self from judgement
nd allow some healthcare engagement, but also can be detrimental,
recluding care seeking for HCV. 
Northrop (2017) also draws on the way in which stigma manifests
hrough the attitudes and actions of healthcare workers as a form of
ole engulfment. Here, the cognitive processes of healthcare workers
re foregrounded in relation to their classification of information and
atients according to clinical characteristics as well as medical and so-
ial norms. This psychological framing again concentrates attention on
tigma as manifest through interpersonal interactions and their effects.
orthrop (2017) highlights the way in which conflation of HCV with
ractices deemed socially unacceptable, such as injecting drug use, can
nfluence (intentionally or not) attitudes towards and treatment of the
ndividual. By subsuming identity to a perceived stereotype or practice,
he healthcare worker can cause the patient to feel unsafe or undeserving
f care. As demonstrated also by Cama et al., 2015 , this limited recogni-
ion of full personhood can impair clinical judgement, impact treatment
rovision and, ultimately, exacerbate health inequalities. 
Harris’ (2009a) exploration of stigma as experienced by people liv-
ng with HCV in New Zealand and Australia, also highlights the way in
hich stigma can manifest through interpersonal interactions as a form
f ‘role engulfment’: 
‘At the mental health unit [I said] I’ve got hep C and she [the health-
care worker] said, ‘Ah, so you are a junkie.’ And I went, ‘No, you are
judgmental’, and then her whole tone changed to, ‘So what drugs do
you use, how much drugs do you use, do you use heroin?’ . . . From
the minute I said hep C her whole demeanour changed (Annie, 41)’
( Harris, 2009a , p. 38). 8 As Harris (2009a) elaborates, the positioning of HCV as a ‘master
tatus’ ( Becker, 1963 ) by the healthcare worker results in Annie leaving
he encounter without having her mental health concerns addressed.
ot only was Annie’s multifaceted identity delimited to the singularity
f a presumed ‘junkie’, but her specific mental health concerns were sub-
umed to concerns about and causative assumptions pertaining to illicit
rug use. Harris explains further that limiting Annie’s full personhood
an impact not only her sense of self but also her trust in and subsequent
uture engagement with the medical system. 
Studies also demonstrate how normative ascriptions of a ‘master sta-
us’ according to specific practices or lifestyle choices can act to cohere
nd create a sense of community or solidarity amongst otherwise dis-
arate individuals. In these works, shared ownership of a practice or
ondition can diminish the weight given to and impact of any associated
tigma. This is highlighted in work addressing HIV activism amongst
ommunities of men who have sex with men (MSM) ( Owen, 2008 ) but
lso can impact how stigma is differentiated in relation to other prac-
ices. Three studies, for example, conceptualise stigma as ‘hierarchically’
nacted in a context of group norms and solidarity ( Lekas et al., 2011 ;
wen, 2008 ; Pecheny et al., 2007 ). In one study amongst communities
f MSM, HIV was seen as more accepted than HCV, with group owner-
hip of HIV enacting greater protection against broader societal stigma
han afforded to HCV ( Owen, 2008 ). Amongst communities of people
ho inject drugs, this dynamic was framed as operating in the opposite
irection ( Harris, 2009b ). Two studies revealed that in some cases how-
ver, lack of awareness about, or ownership of, an associated ‘deviant’
ractice can diminish stigma ( Lekas et al., 2011 ; Pecheny et al., 2007 ).
ekas et al. (2011) illustrates this in relation to some people living with
IV and HCV, for whom HCV is decoupled from its morally charged
oute of transmission and seen purely as a physical ailment. Here, ‘de-
iant’ practices cannot assume the master status of the individual and
elt stigma is diminished ( Lekas et al., 2011 ). 
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a  mbodiment 
Ten of the 13 studies conceptualised HCV stigma as also act-
ng on and through processes of embodiment, with particular refer-
nce to the way in which HCV contravenes binary norms of bod-
ly containment and ‘health’ ( Butt et al., 2008 ; Cama et al., 2015 ;
raser & Treloar, 2006 ; Harris, 2009a ; Krzeczkowska et al., 2019 ;
ekas et al., 2011 ; Moore, Hawley, & Bradley, 2008 ; Northrop, 2017 ;
aterson et al., 2013 ; Pecheny et al., 2007 ). HCV, as a blood-borne
irus, is typified by associations with chronicity and contagion. Trans-
ission via blood is a transgression – an effect of boundless embodiment.
ekas et al. (2011) show how this can cascade to threaten all aspects of
nteraction, as indicated in quote from a 52-year-old Puerto Rican man:
‘Well, there I would say that the majority of the people think that the
person who has hepatitis C is a danger; that’s the first one. If they are
aware that you have that kind of illness, what they do is that they
exaggerate everything. If you go to eat in someone’s home and they
know you have that, the first thing is that they separate the plate
and separate the spoon, no kisses on the lips, and be very careful,
you know’ ( Lekas et al., 2011 , p. 1213). 
Here, the body is always manifest, thus it can be difficult for people
iving with HCV to dissociate from their embodiment as ‘an agent of con-
agion’ ( Northrop, 2017 p. 219). Fears of embodiment, reactions of san-
tary hypervigilance, and/or ‘othering’ have a long history as elucidated
y theorists, such as Mary Douglas (1966) , particularly when blood en-
ry or egress is associated with a ‘non-normative’ bodily opening, such as
ntravenous injection ( Harris, 2009a ). As Fraser and Treloar (2006) ex-
lain, blood positive with HCV is seen as contaminated or ‘dirty’ (p.
03), a potentially immutable status, as indicated by 71-year-old Mona:
‘I guess you feel like it’s kind of dirty… it’s never going to come back
as clean blood’ ( Fraser & Treloar, 2006 , p. 103). 
Similar to Mona, participant accounts across the studies suggest a
ne line between ‘It’s kind of dirty’ and ‘I’m kind of dirty’. Here, a per-
eived pollution of the body, or the blood, cascades to the ‘polluted or
erilous’ self ( Northrop, 2017 , p. 219). Actions to protect the self from
hese attributions can preclude needed care engagement as highlighted
y Northrop (2017) : 
‘One of the reasons why I really just can’t face treatment is that I
really don’t want to deal with the nurse’s reactions to me. I don’t
want to feel like I’m dirty or diseased, or that I’ve done something
bad or wrong to end up there. And I don’t want to deal with their
reactions to me, not treating me like they should’ ( Northrop, 2017 ,
p. 221). 
These accounts highlight the symbolic meaning and implied morality
f cleanliness as a ‘virtue’, which can serve to regulate social relations
hrough, for example, HCV risk management ( Davis & Rhodes, 2004 ).
s explored in five studies, this embodied stigma or perception of pol-
ution can be exacerbated by common misconceptions about HCV and
ts transmissibility ( Butt et al., 2008 ; Cama et al., 2015 ; Harris, 2009a ;
ekas et al., 2011 ; Moore et al., 2008 ) whereby individuals with
CV are perceived as more contagious than they actually are. Lekas
t al. describes ‘hygienic degradation rituals’ (2011; p. 1212) per-
ormed as an extreme or hypervigilant measure to avoid HCV trans-
ission, as evident in the cutlery and dish separation described above.
oore et al. (2008) provide an example of how ignorance about HCV
an cause people to take extreme precautions in such a manner: 
‘A co-worker thought I was contagious and used to spray Lysol on
me not to get it’ ( Moore et al., 2008 , p. 98). 
Lekas et al. (2011) refer to the perception of the body as a ‘vector of
nfection’ when acts like these occur. The distress they cause is a product
f embodiment stigma. 9 Two studies elaborate on how, for people living with HCV, the em-
odied experience of this illness also fails to fit within normative binary
oundaries of illness ( Harris, 2009a ; Henderson & Kawakami, 2018 ). It
s chronic and, until recently, lacked a simple efficacious cure. Sympto-
ology is ill-defined and poorly recognised, thus individuals with the
irus may have their health and ability compromised but appear to
e well. Harris (2009a) highlights participants reports of debilitating
CV symptoms (chronic fatigue, nausea, cognitive confusion or ‘brain
og’) and how their unpredictability of duration or intensity can hin-
er commitment to social or work engagements. Participants who ap-
eared ‘well’ and/or were reluctant to disclose their HCV recounted
istress and frustration at the lack of recognition experienced for their
ymptomology. Being perceived as ‘malingering’ amplified felt stigma
nd guilt when unable to undertake work or social expectations (see
lso Henderson & Kawakami, 2018 ). This could result in further dis-
ngagement from social relations, impacting on support available and
are seeking opportunity ( Harris, 2009a ). These works are valuable in
urther unpacking the way in which HCV stigma operates as a social
onstruct and is imbued within the lived and social body, but as with
dentity-based conceptualisations, they risk individualising stigma un-
erstandings and response. Below, we turn to works in which stigma is
ighlighted as manifest within institutional and structural relations. 
nstitutionalisation 
Three studies conceptualised HCV-related stigma as embodied in and
built’ through physical or institutional structures, or the lack thereof,
nd the social processes to which they lend themselves ( Henderson &
awakami, 2018 ; Moore et al., 2008 ; Paterson et al., 2013 ). Specifically,
he distinct features of these structures and social processes build and
erpetuate HCV-related stigma. For example, Moore et al. (2008) de-
cribe that within the healthcare setting, healthcare professionals and
he institutional policies governing the rules of healthcare practice (e.g.,
riage, security, and confidentiality procedures) can interplay to pro-
uce and exacerbate HCV stigma. Similarly, Paterson (2013) argues that
he confluence of communication, institutional, and departmental struc-
ures within healthcare systems generates structural stigma toward peo-
le living with HCV, particularly those who use illicit drugs. These stud-
es both described gratuitous ‘flagging systems’ to make personnel aware
f individuals with HCV within the healthcare system. 
‘What upset me was, I happen to see my ’folder’ and taped across it
in big black letters on red tape ‘Hep C’ ( Moore et al., 2008 , p. 99). 
Here, the systems and forms of communication used within health-
are settings facilitate stigmatisation by normalising HCV as a contagion
hreat and those who carry it as an ‘other’ to be avoided. 
The apparent visibility of these flagging systems, which go beyond
ecessary infection control procedures and may violate patient privacy
to other patients, visitors, and staff), can be experienced as additionally
ehumanising through contravention of confidentiality concerns: 
‘Two participants […] stated that there had previously been a flag-
ging system within one hospital on patient charts ‘and a sign on the
door to warn staff’ that the patient was HCV positive’ ( Paterson et al.,
2013 , p. 474). 
Paterson et al. (2013) notes that this may be a way for practitioners
o quickly privilege the health of individuals whose illness are perceived
s not self-inflicted, meaning that they are regarded as more deserving of
are. They also note that the stigmatisation of people with HCV through
his process is exacerbated by institutional constraints of health facili-
ies, such as extended waiting times or the absence of dedicated staff
 Paterson et al., 2013 ). This demonstrates how silence can also act to
mbed stigma in the built environment. The absence of safe or dedi-
ated spaces for HCV testing and treatment informs structural stigma
hrough negating the specific needs of affected populations. Henderson
nd Kawakami (2018) elucidate how an absence of investment in HCV
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l  revention, treatment, and care perpetuated ‘long held attitudes [about
he ‘lower class’] including social stigma of HCV’ (p. 3086). Similarly,
he lack of expertise of general health staff and the absence of specialist
taff to address HCV, such as addiction and mental health specialists,
an perpetuate stigma through generating unsuitable, and often nega-
ive, responses towards people with HCV, especially those who use drugs
 Paterson et al., 2013 ). Within healthcare settings, this is embedded both
hysically, by the absence of private spaces for people to disclose their
CV status, and systematically, by the absence of referrals to and from
ommunity services ( Paterson et al., 2013 ). Policies that preclude or
roblematise access to preventative healthcare, such as denial of safe
njecting equipment in custodial or hospital inpatient settings, also act
o silence through negation of needs, usually met in community settings
 Treloar et al., 2016 ). This is also structurally built by wider govern-
ental policies criminalising drug use ( International Network of People
ho Use Drugs, 2021 , which act to socially reinforce stigma against
eople who use drugs and, in doing so, perpetuate inequity of opportu-
ity and care ( Pecheny et al., 2007 ). Stigma here is structurally enacted
oth through silencing a population and denying them the opportunity
o have their needs met. 
Stigma is also structurally enacted through health practitioners’ dis-
lay of hygienic degradation rituals ( Lekas et al., 2011 ), which am-
lifies the feeling of “otherness ” for those with HCV. Studies high-
ighted healthcare professionals taking unnecessary precautions once
articipants’ HCV status was disclosed. These included putting on
ouble gloves, plastic shields, and closing off rooms when provid-
ng care for with people with HCV, none of which are effective or
ecommended practices for providing treatment ( Moore et al., 2008 ;
orthrop, 2017 ; Paterson et al., 2013 ). Whether codified as institutional
olicies in healthcare settings, or the actions of lone practitioners, the
ower imbalance represented here can thwart action. As highlighted by
oore et al. (2008) , the only option for many, as with this participant,
s to disengage: 
‘I had been going to a dentist for a year or so when I found out I had
Hep C. The next time I went to see him, I told him of it. The next
time I came, he was dressed in head to foot coverup with plastic type
shield (like welder’s masque) over his face. I was so humiliated that
I never went back’ ( Moore et al., 2008 , p. 99). 
tructuration 
Power and structure irrevocably interlink in the mobilisation of
tigma as highlighted by Henderson and Kawakami (2018) . In the con-
ext of a small rural community, they foreground the role of the built
nvironment in not only perpetuating stigma through silencing, but
n demarcating informal spaces (such as restaurants) in which those
ith a disposable income can meet, discuss, and define community
oncerns, build consensus, and consolidate power. Two other studies
 Fraser & Treloar, 2006 ; Treloar et al., 2016 ) provide an analytic focus
n power as it pertains to HCV stigma – following broader recognition
f the need to incorporate a thoroughgoing account of power relations
n stigma conceptualisation ( Link and Phelan’s (2001) ; Parker & Ag-
leton, 2003 ). Parker and Aggleton (2003) , for example, position HIV
tigma as functioning at the ‘intersection between culture, power and
ifference’ (2003, p. 17). It involves the categorisation and construction
f differences between people, and, through this, their unequal inser-
ion into systems of power. Fundamentally, this serves to position indi-
iduals into the hierarchy of deservedness for care and other resources
 Paterson et al., 2013 ). 
For Henderson and Kawakami (2018) HCV stigma is ‘built’ within ru-
al communities from a confluence of entrenched social norms, power
ierarchies, and structural inequalities. Rather than HCV or drug use per
e, low socio-economic status acts to demarcate a sector of the popula-
ion as the ‘other’. HCV stigma entangles with poverty – both entrenched
hrough silencing mechanisms by those with the power, social status,10 nd/or financial resources to influence funding decisions. Budget pri-
ritisation is for community ‘beautification’ rather than alleviating eco-
omic hardship and health inequalities. HCV, positioned as a concern
f the ‘lower class’, is negated. It literally ‘does not exist’: 
‘One of the waitresses said sarcastically: ‘[Hep C] doesn’t exist [in
the eyes of the upper-class people]!’ This lack of recognition from the
upper ‘clique’ impacted the amount of help the community provided
to issues relating to hepatitis C ’ (Henderson, 2018, p. 3091). 
The authors attribute the continued increase in HCV cases and other
nfectious diseases in the rural community to this lack of recognition
nd inaction in providing adequate HCV prevention. Power disparity,
rising from social status and income inequality, perpetuates infection
ue to the lack of action by those with the power to enact structural
olutions. 
Similar to Henderson et al.’s (2018) mobilisation of class structures
nd poverty to demarcate HCV stigma, Treloar et al. (2016) draw on cul-
ural attributions of value and worth to unpack the labelling and devalu-
ng of Aboriginal Australians with HCV. Cultural attributions of value
nd worth are critically important mechanisms through which power is
xercised ( Bourdieu, 1987 ). The stigma associated with being Aborigi-
al in contemporary Australia stems from colonial legacies of cultural
ppropriation and decimation that have embedded Euro-centric attri-
utions of worth and associated structural inequalities into the fabric
f current Australian society. Treloar et al.’s (2016) Aboriginal partici-
ants described an ‘automatic expectation’ that they would be ‘Othered’
nd judged as having stigmatised conditions, like HCV: 
‘I think I would have to say that the automatic racist attitude that,
you know, you’ll come up against, you know, like, I expect you to
have these things, you are black. Very negative things’ ( Treloar et al.,
2016 , p. 24). 
Treloar et al. (2016) , highlights how the stigma of having HCV in-
ersects with the stigma of being Aboriginal. Here, having HCV is a
negative thing’, affirming an expected designation as ‘other’ by non-
boriginal Australians. Culturally ascribed labels and stereotypes man-
fest power through upholding social hierarchies based on a history of
uropean expansionism and conquest, which are further perpetuated
hrough ongoing practices of colonisation and structural racism. For
boriginal Australians, as with people who inject drugs and/or who
ive in poverty, engrained social ascriptions of ‘worth’ can elicit shame
 Treloar et al., 2016 ). In this way, stigma serves to further exclude
hese groups from the rest of society. Moreover, this has serious nega-
ive consequences in terms of care, treatment, and overall health. A low
ense of self-worth may convince some individuals that they are unwor-
hy of healthcare, thus thwarting care seeking impetus and opportunity
 Rhodes et al., 2013 ). 
iscussion 
Our findings support a body of work evidencing the deleterious
nd pervasive impact of HCV stigma on concepts of self, social re-
ations, and access to as well as quality of care, described here as
hemes of ‘identity’, ‘embodiment’, ‘institutionalisation’, and ‘structura-
ion’. Whilst commonly deployed as a framing concept in qualitative
tudies seeking to unpack the social relations of HCV and related care,
tigma is often a concept taken-for-granted, implicitly described, and
arely explicitly deliberated in research. Conscious that the social con-
truct of stigma is open to variation according to how it is deployed in
esearch as well as how it might be theorised in different methods and
pistemologies, we synthesised qualitative research deploying ideas of
tigma in relation to HCV to reflect on how the concept is used and
ow we might better delineate stigma concepts in HCV social research
oving forward. 
Our first observation is a tendency for stigma to be produced and
ocated in relation to individuals, as a matter of how discriminatory
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t  eliefs and attitudes shape social and self-identity. Here, stigma is mo-
ilised in research as an effect or consequence that is felt, made man-
fest, and observed in individuals. Paterson et al.’s (2007) conclusion
rom their review, that the majority of studies addressing HCV stigma
nd discrimination employ individualistic psychological models of stig-
atisation, is still prescient. Positioning stigma as arising from, and re-
iding in, individual practices and attitudes, obscures how stigma might
e alternatively located and produced in wider social, political, and
conomic contexts. We note, for example, a recent systematic review
f the qualitative literature on living with HCV that includes synthe-
is of findings related to stigma causes and responses ( Dowsett et al.,
017 ). Here, the individual and the interpersonal interaction is high-
ighted as the site of stigma; stigma is caused by associations with non-
ormative risk practices (‘deviant identities’), fear and/or mispercep-
ions regarding transmission. Reported responses and actions orientate
oward shame, anger, isolation, non-disclosure, and (less commonly)
ducating others. These findings align with those thematised against
identity’, but neglect consideration of the way in which stigma is oper-
tionalised and institutionalised more broadly. As we elaborate below,
tigma is felt and located in individual bodies, but this lived experience
annot be separated from social relations; rather it is a recursive effect of
hese. 
HCV stigma is structured and perpetuated by the policies and built
nvironments which support certain social processes, such as criminali-
ation of drug use and physical arrangements of healthcare institutions.
ithin this context, societal disavowal and fear of chronic illness in
ddition to moral assumptions of practices associated with HCV are
obilised to differentiate those with HCV as the ‘other’. This ‘social
riage’ ( Nguyen, 2010 ) positions those with HCV in the hierarchy of
eservedness for health and social resources and care ( Paterson et al.,
013 ). For example, HCV stigma commonly manifests as the confla-
ion of HCV with certain high-risk and socially demonised practices,
uch as injection drug use. Given the social perception that health is
n individual responsibility rather than a product of wider structural
orces ( Peterson & Lupton, 1996 ; Turner, 1984 ), this presupposes that
ndividuals with HCV are ‘less than fully acceptable patient citizen[ s ]’
 Rhodes et al., 2013 , p. 1040) and therefore unworthy of high quality
are or even any care at all. Fundamentally, this stigmatisation process
ails to recognise the various identities, and roots of these identities, of
hose with HCV, which problematises meeting their health and social
eeds. 
It is important then, to foster conceptualisations of stigma which
ncorporate the ‘social’ as elements of what makes up individual-level
tigma effects. Embodiment in this interpretation, and as our synthesis
f the qualitative literature indicates, refers to the incorporation of the
ocial. The stigmatised human body is not merely symbolic of a social
ody and of social norms (for instance, through the discrimination of
ertain bodies from inclusion or representation in public, populations,
ommunities, and services), but material, in the sense that individual
odies become the corporeal hosts of structural harms (for instance, ex-
ibiting unequal ill health, risk, and felt discrimination). Similar to HIV
tigma related to drug use, HCV stigma is a social process, linked to and
mbedded within other forms of marginalisation, which can exacerbate
ealth inequalities and thus access to care ( Collins et al., 2016 ; Parker &
ggleton, 2003 ). Furthermore, stigma is associated with levels of com-
unity awareness and attitudes about people living with HIV, in parallel
o what we found about HCV stigma in terms of community support and
roup solidarity mitigating stigma ( Van Nguyen et al., 2017 ). This high-
ights the need for thinking of stigma in relation to matters of a social
ody, rather than simply in relation to individual human bodies, which
s also important for practical reasons, as Metzl and Hansen (2014) note,
n regard to clinical practice: 
‘If stigmas are not primarily produced in individual encounters but
are enacted there due to structural causes, it then follows that clinical
training must shift its gaze from an exclusive focus on the individual
d  
11 encounter to include the organisation of institutions and policies …
if clinicians are to impact stigma related health inequalities’ ( Metzl
& Hansen, 2014 , p. 128). 
This leads us to consider how embodiments of stigma might be the-
rised as structural concerns. 
Here, Metzl and Hansen (2014) propose a framework of ‘structural
ompetency’ for imagining how healthcare can be provided in ways that
ecognise and address the social basis of ill health, stigma, and other vul-
erabilities. Structural competency finds affinity with socioecological
odels, which emphasise health and illness as effects of structuration
nd structural vulnerability, meaning that it is shaped by wider envi-
onmental, political, cultural, and socio-economic forces ( Rhodes et al.,
012 ). For example, Bagchi (2020) put forth a structurally competent
urriculum for primary care providers in the United States to address
pioid use disorder, HIV, and HCV, and their associated stigmas. This
urriculum provides concrete examples of how structural forces can be
endered visible in the clinical encounter to recognise harms, reduce
tigma, and thus provide a people-centred approach to care. Integral
o this course is the emphasis on the historical and social factors that
ave influenced injecting drug use as well as its risks and consequences
n the United States, including the role of pharmaceutical companies
n opioid medication advertisements, the racial consequences of the
War on Drugs’ and mass incarceration, and the lack of federal fund-
ng prioritisation for HIV and HCV treatments. The curriculum also in-
ludes tools to assess structural vulnerability and encourages providers
o consider structural factors in their explanation of health outcomes
 Bagchi, 2020 ). 
Additional examples of structural interventions to enhance HCV
reatment access and uptake include the development of ‘enabling en-
ironments’, such as through flexible modifications to appointment sys-
ems, treatment locations, and eligibility requirements ( Harris, Rhodes
 Martin, 2013 ). Low threshold community-based testing and treat-
ent provision, including through peer-led initiatives ( Surey et al.,
019 ; Wade, Veronese, Hellard, & Doyle, 2016 ), can mitigate stigma by
hallenging the ‘arrogant authority’ ( Hansen & Metzl, 2019 ) often en-
renched in hospitals and other traditional healthcare settings. As with
oves toward ‘structural competency’, principles of ‘cultural safety’ also
ork to develop clinical awareness of political and social dimensions
f health outcomes and care, with a focus on recognising and ame-
iorating interactions, practices, and structural frameworks that cause
arginalised populations to feel unsafe and powerless in healthcare en-
ironments ( Curtis et al., 2019 ; Gerlach, 2012 ). Originating from nurs-
ng care for indigenous populations, cultural safety training has been
uccessfully adapted to promote care for people who inject drugs in the
anadian context ( Pauly, McCall, Browne, Parker, & Mollison, 2015 ).
uthors argue that providers should consider their own place of priv-
lege and power within their relationship with the patient. Providers
ust also reflect on how this power imbalance may generate a gap in
rust, which may be further eroded by the deployment of stereotypes
e.g. of ‘addicts’) in the health setting by perpetuating blame and as-
uming individual responsibility for health ( Pauly et al., 2015 ). Associ-
ted hospital-based interventions, such as provision of injecting equip-
ent for inpatients, promote not only safe injecting but send a potent
ymbolic signal of recognition and acceptance – thus enhancing stigma
eduction and care equity more broadly. 
The examples above are of small structural changes in clinical prac-
ice and training that can have far reaching impact. To paraphrase Metzl
nd Hanson (2014) by acting on ‘the pathologies of social and institu-
ional systems’ we can ‘impact the material realities of people’s lives’
p. 129). It is crucial therefore, to look beyond explanations and the-
risations of stigma as produced and located in relation to individu-
ls, as a matter of how discriminatory beliefs and attitudes shape social
nd self-identity. This can lead to narrowly focused educational or atti-
udinal interventions. Such interventions can act in part to ameliorate
iscriminatory social relations through enhancing awareness, but they
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ltimately fail to support sustained change by neglecting to address the
roader social structural context in which stigma is supported, perpet-
ated, and normalised. As noted in this review, stigma is also socially
tructured through processes of silencing. An absence of safe or dedi-
ated spaces for people who use drugs to receive HCV care, for exam-
le, can perpetuate health inequalities through dissuading access. As
enderson and Kawakami (2018) illustrate, the stigma experienced by
heir participants living with HCV entangles with poverty and together
hese interplay to enact a population as ‘other’ and negate their concerns
hrough limited allocation of resources. Stigma here, is not explicit, but
nacted as a social process which locates beyond individuals, whilst en-
angling them, and matters of personal and social identity, inside wider
ocial relations. 
Stigma is then a dynamic and complex process ( Seear, 2020 ). It man-
fests in interactions amongst individuals, practices, and communities-
f-practice. Such interactions take place within moral and political
conomies of social exclusion, which are shaped by cultural distinc-
ions of value and worth ( Bourdieu, 1987 ; Parker & Aggleton, 2003 ).
s such, socially codified binaries – good/bad, healthy/ill, accept-
ble/unacceptable – are expressed across various power arrangements
from the local to the global) that allow stigma to persist. Thus, stigma
nterventions must trouble and disrupt binary logics which afford stigma
he possibility to work as an act of power in relation to a certain imag-
ned norm or boundary. This highlights the need for stigma interven-
ions to focus on the interactions which produce stigma effects, that it is
either a simple matter of capacitating individuals, nor a simple matter
f adapting structures, but rather recognising and addressing how these
oth interact in a recursive fashion in a particular setting. Therefore,
uture applications of research on viral hepatitis must move towards
learly mapped conceptualisations of stigma, and conceptualisations of
tigma must emphasise its inter-relational and multifaceted characteris-
ics in specific settings. Stigma, then, manifests as both social practice
nd lived realities, based on its research and other situated implemen-
ations ( Fraser et al., 2017 ; Rhodes & Lancaster, 2019 ). 
imitations 
Our review is subject to several limitations. First, the review may
ave been impacted by publication bias as we only included peer-
eviewed studies. Although, given the topic of this study, grey literature
ill most likely not make up a substantial portion of the knowledge base.
econd, we only aimed to include papers published in English and Span-
sh, which may have influenced the geographical distribution of papers.
he studies we included primarily came from high-income countries,
nd HCV stigma may manifest differently in this context compared to
he low- and middle-income countries ( Nguyen et al., 2019 ). Third, the
eview may be subject to selection bias due to the necessary interpretive
ork required to delimit empirical qualitative research that also incor-
orated explicit conceptualisation or theorisation of stigma. Lastly, the
eview methodology may have affected the search results and findings
f this study since we excluded papers that may have implicitly rather
han ostensibly theorised or conceptualised stigma in relation to HCV.
owever, the precision and rigid nature of this method allows for a bet-
er insight into the knowledge base and can serve as a foundation for
uture research on this topic. 
onclusion 
Much of the work of hepatitis C and its related stigma fails to explic-
tly conceptualise or define stigma. A shared understanding is assumed
r taken-for-granted, problematising the effective development of in-
erventions to mitigate stigma and enhance access to HCV diagnostics,
are, and treatment. Our synthesis of the conceptual literature on HCV
tigma provides nuance by moving beyond identity or attribute-based
onceptualisations of stigma to unpack how stigma operates as a rela-
ional process - constituted in an interplay of social, structural, material,12 nd embodied relations. As such, interventions to mitigate the impact
f stigma must be multifaceted, and attend both to the structural, or-
anisational, policy, and social environments in which stigma is built as
ell as how it plays out in individual interaction. Future research mo-
ilising stigma as a framing concept must engage more critically with
tigma as a multiple and relational category that emerges in specific
ays according to its contexts. 
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